BioEclipse Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • BioEclipse Therapeutics's estimated annual revenue is currently $1M per year.(i)
  • BioEclipse Therapeutics's estimated revenue per employee is $77,500

Employee Data

  • BioEclipse Therapeutics has 13 Employees.(i)
  • BioEclipse Therapeutics grew their employee count by 0% last year.

BioEclipse Therapeutics's People

NameTitleEmail/Phone
1
Director Contract AdministrationReveal Email/Phone
2
Associate Scientist, Analytical DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.4M70-8%$53MN/A
#2
$32.4M167-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.8M1813%N/AN/A
#5
$0.8M5-50%N/AN/A
#6
$0.8M100%N/AN/A
#7
$14M90-12%N/AN/A
#8
$0.4M33610%$236.7MN/A
#9
$4.8M62-74%$160MN/A
#10
$3.7M24-8%N/AN/A
Add Company

What Is BioEclipse Therapeutics?

BioEclipse Therapeutics™ is a clinical-stage oncology company that uses its proprietary technology to develop the next generation of immuno-oncology therapeutics. Foundationally, we have harnessed a refined understanding of the human immune system, gaining insights into the reasons the body’s defense system so often turns a blind eye to the presence of cancerous cells and tumors. In response, BioEclipse Therapeutics™ pairs activated immune cells with an adapted oncolytic virus that selectively infects and kills malignant cells. The result of this combination is a multi-mechanistic, targeted treatment that we believe will not only eradicate cancer cells, but also protect the patient from relapse and recurrence, through a durable immune response that prevents the development of new cancers, even in the face of new challenges from disease.

keywords:N/A

N/A

Total Funding

13

Number of Employees

$1M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.6M13-28%N/A
#2
$3.3M138%N/A
#3
$0.4M13-7%$12M
#4
$0.5M13160%N/A
#5
$1.6M13N/AN/A